微生态制剂联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效
那妍, 娄宪芝沈阳医学院附属中心医院感染科, 沈阳 110024
收稿日期:
2019-10-24出版日期:
2020-02-29发布日期:
2019-12-26通讯作者:
那妍E-mail:781107@qq.com作者简介:
那妍(1978-),女,副主任医师,硕士.基金资助:
辽宁省自然科学基金(20170540882)关键词: 乙型肝炎, 肝硬化, 恩替卡韦, 微生态制剂, 双歧杆菌四联活菌片
Abstract: Objective To evaluate the efficacy of entecavir combined with probiotics in patients with hepatitis B virus-related cirrhosis. Methods Eighty patients with hepatitis B virus-related cirrhosis admitted to our hospital between January 2017 and December 2018 were included in this study. The patients were randomly divided into the control group(entecavir treated)and the study group(entecavir plus probiotics treated). After 6 months,the treatment efficacy in these two groups was assessed,based on the incidences of fatigue,abdominal distension,and anorexia,and changes in the indicators of liver function and fibrosis. Results The incidences of fatigue,abdominal distension,and anorexia decreased after treatment in both groups and were lower in the study group than in the control group (P<0.05). Similarly,the levels of glutamic-pyruvic transaminase,glutamic-oxaloacetic transaminase,total bilirubin,hyaluronic acid,procollagenⅢ, and laminin decreased after treatment in both groups and were lower in the study group than in the control group(P<0.05). Conclusion Entecavir combined with probiotics has a better therapeutic effect compared to entecavir monotherapy in patients with hepatitis B virus-related cirrhosis.
Key words: hepatitis B, cirrhosis, entecavir, probiotics, Bifidobacterium tetragenous viable bacteria
PDF全文下载地址:
https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=2439